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Background: Economic implications of chemotherapy-induced febrile neutropenia (FN) in European and Australian
clinical practice are largely unknown.
Methods: Data were obtained from a European (97%) and Australian (3%) observational study of patients with
non-Hodgkin’s lymphoma (NHL) receiving CHOP (±rituximab) chemotherapy. For each patient, each cycle of
chemotherapy within the course, and each occurrence of FN within cycles, was identified. Patients developing FN
in a given cycle (“FN patients”), starting with the first, were matched to those who did not develop FN in that cycle
(“comparison patients”), irrespective of subsequent FN events. FN-related healthcare costs (£2010) were tallied for
the initial FN event as well as follow-on care and FN events in subsequent cycles.
Results: Mean total cost was £5776 (95%CI £4928-£6713) higher for FN patients (n = 295) versus comparison
patients, comprising £4051 (£3633-£4485) for the initial event and a difference of £1725 (£978-£2498) in
subsequent cycles. Among FN patients requiring inpatient care (76% of all FN patients), mean total cost was
higher by £7259 (£6327-£8205), comprising £5281 (£4810-£5774) for the initial hospitalization and a difference of
£1978 (£1262-£2801) in subsequent cycles.
Conclusions: Cost of chemotherapy-induced FN among NHL patients in European and Australian clinical
practice is substantial; a sizable percentage is attributable to follow-on care and subsequent FN events.
Keywords: Febrile neutropenia, Costs and cost analysis, Non-Hodgkin’s lymphomaBackground
Neutropenia is a common side effect of myelosuppressive
chemotherapy. Neutropenia both increases the risk of in-
fection and diminishes patients’ ability to fight infection.
Since fever is a cardinal sign of infection, when neutro-
penic patients develop fever (i.e., febrile neutropenia
[FN]), the high likelihood of infection and serious conse-
quences usually necessitates hospitalization for urgent
evaluation, ongoing monitoring, and administration of
intravenous antibiotics. FN, as well as severe or prolonged
neutropenia, can lead to dose-delays, dose-reductions,
and/or chemotherapy discontinuations, interfering with* Correspondence: dweycker@pai2.com
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reproduction in any medium, provided the orthe delivery of optimal treatment and possibly adversely
affecting patient outcomes [1-5].
The economic cost of chemotherapy-induced FN is sub-
stantial [6-8]. In one study, the mean cost of FN-related
hospitalizations in the US was reported to be $8100 for
patients with solid tumors, $11,600 for patients with non-
Hodgkin’s lymphoma (NHL), and $28,000 for patients
with leukemia [7]. It is likely, however, that this study--as
well as other studies utilizing a cross-sectional design and
hospital records--underestimated the total economic bur-
den of FN, since the cost of follow-on care (e.g., post-
discharge outpatient encounters) and subsequent FN
events that may be related to the (initial) FN event were
not considered. In a more recent US study employing a
matched cohort design and considering all such costs, thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to represent only about 60% of the total cost of FN-
related care, suggesting that prior studies may have un-
derestimated the mean cost of FN-related events by as
much as 40% [9].
Relatively little is known about the economic burden
of chemotherapy-induced FN in European and Austra-
lian clinical practice, however, and no studies conducted
outside the US have considered the burden of care for
the initial FN event as well as the downstream conse-
quences of the initial event. The current analysis, there-
fore, was undertaken to evaluate the full economic
impact of FN among NHL patients receiving chemother-
apy with cyclophosphamide, doxorubicin, vincristine,
and prednisolone every 14 or 21 days (i.e., CHOP-14
or CHOP-21) in geographically diverse centers across
Europe and in Australia.
Materials and methods
Study setting and source population
Data for this study were obtained from a large combined
retrospective/prospective observational evaluation of
supportive care among NHL patients receiving CHOP-
14 or CHOP-21 chemotherapy in geographically diverse
centers primarily across Western and Southern Europe
(97% of patients) and in Australia (3% of patients). The
design of this study, termed the “IMPACT NHL Study”
(ClinicalTrials.gov: NCT00903812), is described in detail
elsewhere in the literature [10-13]. In countries where it
was required, ethical approval of the IMPACT NHL
Study was obtained and patients provided written in-
formed consent.
Briefly, approximately 1800 adult patients with NHL
who were planned to receive at least three cycles of
CHOP-14 or CHOP-21 chemotherapy--with or without
rituximab--were recruited (about 600 retrospectively,
1200 prospectively) from 128 geographically diverse
study centers. Study patients may have received a prior
course of chemotherapy (~9% of study population).
Patients enrolled retrospectively included those who
completed all cycles of chemotherapy--regardless of ac-
tual number of cycles or outcomes thereof--after January
1, 2005 and prior to site participation in the study.
Patients enrolled prospectively included all patients for
whom CHOP-14 or CHOP-21 chemotherapy was planned
for administration between January 2006 and December
2008; no additional interventions were required as a result
of participation in the study. All patients enrolled in the
IMPACT NHL Study (n = 1,864) who met protocol-
defined eligibility criteria and received at least one cycle of
chemotherapy (n = 1,829) were included in the source
population for the current analysis.
For each patient, baseline data were collected on pa-
tient demographics (e.g., age, sex, race, height, weight),medical history (e.g., comorbid conditions), Eastern Co-
operative Oncology Group Performance Status (ECOG
PS), cancer characteristics (e.g., bulky disease, bone mar-
row involvement), International Prognostic Index (IPI)
score (non-follicular patients only)/Follicular Lymphoma
International Prognostic Index (FLIPI) score (follicular
patients only), prior antineoplastic therapy, planned
chemotherapy (i.e., CHOP-14 or CHOP-21, with or with-
out rituximab [“-R”], doses, number of cycles), and pre-
dicted risk of FN (i.e., <20% vs ≥20%). Cycle-specific data
collected during the chemotherapy course included ac-
tual chemotherapy regimen (i.e., drug, dose, date of
administration), use of selected drugs/services (e.g., gran-
ulocyte colony-stimulating factor [G-CSF] for prophylaxis
[primary or secondary] or treatment, erythropoiesis-
stimulating agent [ESA], transfusions, anti-infective agents),
performance status, and occurrence of FN--as well as
selected other adverse outcomes--and associated setting
of care (i.e., hospital, outpatient setting, home). Hospita-
lizations for reasons other than FN were also captured.
Study population
The study population, consisting of patients who experi-
enced FN and matched comparison patients, was
selected from the source population as follows. For each
patient in the source population, all chemotherapy cycles
in which FN occurred were identified. FN was defined as
a single oral temperature of ≥38.30C or a temperature of
≥38.0°C for ≥1 hour, and a neutrophil count of <0.5 x
109/L or a neutrophil count of <1.0 x 109/L that is pre-
dicted to fall below 0.5 x 109/L. Patients with FN in
more than one cycle were classified according to the
cycle number in which FN first occurred.
Patients in the source population who developed FN
during their first cycle of chemotherapy (“FN patients”)
were matched on selected covariates--hypothesized to be
possibly associated with FN and healthcare costs--to
patients who did not develop FN during their first cycle
of chemotherapy (“comparison patients”), whether or
not they developed FN in any subsequent cycles.
Matched cycle-one FN patients and comparison patients
were then removed from their respective pools. From
remaining patients in the source population (i.e., those
not previously matched), those who first developed FN
in their second cycle of chemotherapy were matched to
those who did not develop FN in that cycle. Matched
cycle-two FN patients and comparison patients were
then removed from their respective pools. FN patients
and comparison patients were similarly matched in the
third and all subsequent cycles. The cycle in which
patients were matched was designated the “index cycle”.
Matching was implemented--sequentially, on a cycle-
specific basis--for each FN patient by identifying all can-
didate comparison patients matching that FN patient in
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regimen. The candidate with the closest propensity score
(“nearest neighbor”) to the FN patient was selected as
the matched comparison patient. Matching was con-
ducted for FN patients randomly, and without replace-
ment of comparison patients (i.e., comparison patients
were matched to one FN patient only). Propensity scores
were estimated using multivariate logistic regression; in-
dependent variables included all demographic and
disease-specific characteristics (e.g., age, sex, IPI/FLIPI
score, bone marrow involvement), predicted risk of FN,
presence of (current/continuing) comorbidities, chemo-
therapy regimen, supportive care, ECOG PS, absolute
neutrophil count (ANC), and presence of anemia symp-
toms (e.g., fatigue/tiredness, pallor/pale skin, headache,
dyspnea). All of the above-listed variables--with the ex-
ception of ANC, presence of anemia symptoms, and
supportive care--were characterised using data collected
at baseline in the IMPACT NHL Study; the exceptions
were characterised using data collected during the pre-
index cycles and index cycle, as appropriate.
An alternative, more restrictive matching procedure--
including age (±5 years), country of residence, tumor
stage, bone marrow involvement, IPI/FLIPI score, and
chemotherapy regimen when identifying candidate com-
parison patients--was first employed, but was ultimately
deemed by study investigators to be inadequate due to
small sample size (n = 118). The characteristics of FN
patients and comparison patients matched using this
more restrictive procedure is described in Additional file 1:
Table S1 of the online supplement.
Study measures
FN-related healthcare utilization was tallied for each FN
patient and matched comparison patient from the cycle
in which FN first occurred (for the former) through the
last cycle of chemotherapy. Healthcare utilisation was
examined in terms of: the number of FN events requir-
ing inpatient care, outpatient care, home care, and
other/unknown care, respectively; the total number of
hospital days for all FN-related admissions that occurred
from the index cycle through the end of the last chemo-
therapy cycle; and use--and reason for use--of G-CSF
(pegfilgrastim, filgrastim, and other G-CSF [presumably
lenograstim]) and IV antimicrobial agents by setting of
care. Use of G-CSF and antimicrobial agents as prophy-
laxis was considered in post-index cycles only, while use
of these agents as treatment was considered beginning
with the index cycle.
FN-related healthcare costs were calculated for FN
patients and comparison patients by combining esti-
mates of FN-related healthcare utilization--as described
above--with unit-cost data from the United Kingdom
(UK). UK-specific unit costs were estimated from theperspective of the National Health Service using data
from readily-available secondary sources and published
literature, where available, as well as expert opinion,
where needed. Principal sources of cost data were the
2009–2010 National Health Service (NHS) Schedule of
Reference Costs (hospital costs), the 2010 Unit Costs of
Health and Social Care Report from the Personal Social
Services Research Unit (outpatient, home care, and other
setting costs), and the British National Formulary (BNF),
60th Edition (pharmacotherapy costs) [14]. Unit
costs are set forth in Table 1; a full description of meth-
ods employed to estimate unit costs is provided in
Additional file 1: Table S2 of the online supplement.
Statistical analyses
The adequacy of the matching procedure was evaluated
based on the similarity of matched FN and comparison
patients in terms of their baseline characteristics. Cat-
egorical variables were compared using the McNemar or
Bowker test, and continuous variables were compared
using the paired-samples t-test. The similarity of
matched patients and unmatched patients--in terms of
their characteristics--also was examined.
FN-related healthcare utilization and costs from the
index cycle through the end of the last cycle of chemo-
therapy were examined on a cumulative basis for each
patient in the FN and comparison groups. Mean values
were estimated for the two groups, as well as for differ-
ences between groups, on an overall basis during the
index cycle and during post-index cycles. Hospital days
for FN patients and comparison patients with missing
data on admission/discharge dates were imputed based
on corresponding subgroup-specific mean values. FN-
related healthcare costs also were evaluated among
subgroups of patients defined on the basis of key charac-
teristics, including index cycle, chemotherapy regimen,
and predicted FN risk. Ninety-five percent confidence
intervals (95% CIs) were generated using techniques of
nonparametric bootstrapping.
The appropriateness of combining FN-related health-
care utilization data from different countries with unit
cost information from the UK was evaluated based on a
comparison of country-specific mean numbers of
patients developing FN by setting of care, and for
patients requiring inpatient care, country-specific mean
numbers of hospital days. These analyses were based on
data from FN patients and comparison patients who
were matched on the basis of the criteria set forth above
(i.e., age, tumor stage, chemotherapy regimen, and pro-
pensity score) as well as country of residence. Results
were summarized using means and 95% CIs; formal
statistical tests for heterogeneity between patients in dif-
ferent countries were not undertaken due to small
country-specific sample sizes.
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Patient characteristics
Among the 1829 NHL patients in the source population,
331 (18%) experienced one or more FN events--a total
of 479 FN events--during their course of chemotherapy;
the number of events, by cycle, occurred as follows: 1st
cycle, 128 (27%); 2nd cycle, 64 (13%); 3rd cycle, 67
(14%); 4th cycle, 68 (14%); and 5th or later cycle, 152
(32%). The majority of FN events (77%) required in-
patient care.
A total of 295 FN patients were successfully matched
(1:1)--on age (±5 years), tumor stage, and chemotherapy
regimen, as well as closest propensity score--to compari-
son patients (Table 2). (Selected covariates are presented
in Table 2; a full listing of covariates is provided in
Additional file 1: Table S3 of the online supplement.)
Mean (±SD) age was 63 (±12) years, 69% had stage III
or IV disease, and 91% received CHOP-14-R (28%) or
CHOP-21-R (63%). No covariate differed significantly
between FN patients and comparison patients. Most
patients were matched in cycle 1 (43%) or cycle 2 (14%),
and the mean number of cycles from the index cycle
through the end of chemotherapy was 4.5 (±2.1) for FN
patients and 4.6 (±2.1) for comparison patients. Ninety-
seven percent of the study population received chemo-
therapy at a site in Western or Southern Europe; the
remaining 3% received care in Australia.
Matched and unmatched patients were similar in
terms of many of their baseline characteristics, but
matched patients were older (by about 4 years, onTable 1 UK-specific unit costs of FN-related care
Healthcare Resource
FN Inpatient Care
Long-Stay (per admission)
Excess Bed Days (per d
Short-Stay
Day Case
FN Outpatient/Home/Other/Unknown Care
Outpatient Encounter
Initial Consultation
Follow-Up Consultation
Home Encounter
Other/Unknown Encounter
Drug*
Filgrastm (per 600 mcg
Pegflgrastim (per 6 mg
Other CSF (per day)
IV Antimicrobial Agent
*Units and corresponding costs based on recommended dosing of agents.average) and a higher percentage of them had advanced
disease (58% vs 45%) and a predicted risk of FN ≥20%
(73% vs 61%). These results were not unexpected, since
age and presence of advanced disease are risk factors for
FN, and comparison patients were matched to FN
patients based on these factors. (Data on all baseline
characteristics for matched and unmatched patients are
available in Additional file 1: Table S4 of the online
supplement.)FN-related healthcare utilization
FN patients averaged 1.44 (95%CI 1.34-1.56) FN events
from their index cycle through the end of their course of
chemotherapy--0.44 (0.34-0.56) during post-index cycles--
and comparison patients averaged 0.15 (0.10-0.21) such
events over the same period, corresponding to a difference
of 1.29 FN events (1.17-1.43) (Table 3). Among FN
patients, 76% of index FN events and 79% of post-index
FN events required inpatient care; for comparison
patients, the corresponding percentage (during post-index
cycles) was 84%. Among FN patients requiring inpatient
care, the average number of FN events (irrespective of set-
ting of care) was 1.10 (1.00-1.21) versus 0.13 (0.08-0.18)
for matched comparison patients, a difference of 0.98
(0.85-1.11). Mean number of FN-related hospital days was
6.21 (5.28-7.17) for FN patients versus 0.63 (0.30-1.02) for
comparison patients, a difference of 5.62 (4.64-6.62).
Levels of FN-related healthcare utilization among FN
patients and comparison patients (matched on theUnit Cost
(£)
Source
5361 NHS Reference Costs, 2008–2009 and 2009-2010
ay) 502
772
577
177 NHS Reference Costs, 2009-2010
116
84
26
) 59 BNF, 60th Edition
) 686
63
s (per day) 38
Table 2 Characteristics of FN patients and comparison patients matched on basis of age (±5 years), tumor stage,
chemotherapy regimen, and propensity score
FN Patients
(n = 295)
Comparison
Patients
(n = 295)
P-value*
Demographics
Age, mean±SD, y 63.3 ±
12.4
63.0 ±
12.1
0.108
Male, % 49.0 50.7 0.674
Country of Residence
Australia 2.7 2.7 0.817
Austria 5.8 9.2
Belgium 11.6 11.9
France 24.5 18.4
Germany 10.2 12.2
Greece 2.7 1.7
Italy 5.1 7.8
Netherlands 8.8 8.5
Nordics 7.1 6.5
Portugal 1.4 1.7
Spain 12.6 12.6
Switzerland 2.7 2.4
UK and Ireland 4.8 4.4
NHL
Tumor Stage
I 14.6 14.6 —
II 16.7 16.7
III 19.4 19.4
IV 49.3 49.3
IPI/FLIPI Score
IPI Score
Low 16.4 20.8 0.368
Intermediate 50.4 50.6
High 19.6 17.3
Missing 13.6 11.4
FLIPI score
Low Risk 11.4 15.4 0.920
Intermediate Risk 36.4 23.1
Poor Risk 43.2 51.3
Missing 9.1 10.3
Bone Marrow Involvement 29.6 24.8 0.252
Clinical
Risk of FN, %
<20% 27.0 27.0 0.564
≥ 20% 73.0 73.0
Medical Conditions, %
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Table 2 Characteristics of FN patients and comparison patients matched on basis of age (±5 years), tumor stage,
chemotherapy regimen, and propensity score (Continued)
Cardiovascular Disease 23.5 25.2 0.615
Respiratory Disease 7.8 4.8 0.128
Gastrointestinal Disease 6.1 5.1 0.564
Renal Disease 3.1 3.4 0.796
Hepatic/Biliary Disease 2.7 5.8 0.061
Haematologic/Lymphatic 5.1 3.1 0.221
Immunologic 5.4 3.7 0.317
Other 49.0 46.3 0.505
ECOG PS, %
0 47.6 52.4 0.182
1 31.0 31.6
2 10.2 7.5
3 5.1 3.7
4 1.0 0.7
Missing 5.1 4.1
Hematology
ANC (X10^9L), mean±SD 5.4 ± 4.5 5.7 ± 3.4 0.794
Presence of Anemia Symptoms, % 56.8 56.1 0.856
Treatment
Chemotherapy Regimen, %
CHOP-14 3.40 3.40 —
CHOP-14-R 27.89 27.89
CHOP-21 5.44 5.44
CHOP-21-R 63.27 63.27
Supportive Care, %
Index Cycle
G-CSF Prophylaxis 51.7 56.5 0.162
Anti-Infective FN Prophylaxis 13.3 11.6 0.529
Pre-Index Cycle
G-CSF
Prophylaxis 37.4 41.8 0.074
Treatment 9.5 6.5 0.128
Anti-Infective
FN Prophylaxis 7.8 5.8 0.303
FN Treatment 1.7 0.3 0.102
Transfusion 9.5 6.8 0.144
Index Cycle Number*
1 42.9 42.9 —
2 13.6 13.6
3 11.2 11.2
4 12.2 12.2
5 9.9 9.9
6 8.2 8.2
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Table 2 Characteristics of FN patients and comparison patients matched on basis of age (±5 years), tumor stage,
chemotherapy regimen, and propensity score (Continued)
7 1.7 1.7
8 0.3 0.3
Total Number of Cycles (incl. index cycle thru end of course)
1 10.6 11.2 0.812
2 11.9 9.5
3 13.3 11.6
4 12.3 15.3
5 12.6 11.6
6 24.2 24.8
7 4.1 4.1
8 10.9 11.9
*P-values were not calculated for variables used in the matching process and for which there are no differences between groups (i.e., there was an exact match).
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residence [n = 236]) and corresponding differences be-
tween these groups, were largely comparable across
countries (data available in Additional file 1: Table S5
of the online supplement). Among country-specific
subgroups including ≥15 patients, mean number of FN
events among FN patients ranged from 1.41-1.63, and
mean number of events requiring inpatient care, 0.79-
1.50; the mean number of hospital days among FN
patients ranged from 3.8-5.2.FN-related healthcare costs
Mean overall FN-related healthcare cost among FN pa-
tients was £8066 (95%CI £7277-£8882)--£4051 (£3633-
£4485) during the index cycle and £4015 (£3374-£4724)
during post-index cycles (Table 4). Mean cost of FN care
among comparison patients (for whom all costs were in-
curred during post-index cycles, by design) was £2290
(£1923-£2655). Overall mean cost thus was £5776
(£4928-£6713) higher for FN patients than comparison
patients, with 71% of the difference attributable to care
in the index cycle (£4051 [£3633-£4485]) and 29% attrib-
utable to care in post-index cycles (£1725 [£978-£2498]).
Stratified by the setting of care for the index FN event,
the difference in mean overall cost was greatest for those
who received inpatient care for FN during the index
cycle versus comparison patients who were matched to
them--£9688 (£8709-£10,653) versus £2430 (£1984-
£2931), a difference of £7259 (£6327-£8205). Corre-
sponding results for those patients whose index FN
event was treated in other settings of care were: out-
patient, £3761 (£1908-£6007) versus £1777 (£1116-
£2565); and home care, £3291 (£2445-£4339) versus
£1826 (£993-£2919).Differences in mean FN-related healthcare costs be-
tween FN patients and comparison patients were com-
parable within subgroups defined on the basis of key
characteristics, including index cycle, chemotherapy
regimen, and predicted FN risk. By index cycle, differ-
ences were: cycle 1, £6024 (£4588-£7429); cycle 2, £4913
(£3123-£6875); cycle 3, £6029 (£3409-£9242); cycle 4,
£6804 (£4519-£9543); and cycle ≥5, £5121 (£4084-
£6220). For patients receiving CHOP-14-R and CHOP-
21-R, differences were £5667 (£4002-£7261) and £6045
(£4855-£7173), respectively. For matched FN and com-
parison patients with a predicted FN risk ≥20%, differ-
ence was £5603 (£4603-£6605), and for those with a
predicted FN risk <20%, £6006 (£4557-£7783).Discussion
Using a matched-cohort design, healthcare utilisation data
for 1829 NHL patients receiving CHOP-14 or CHOP-21
chemotherapy in European and Australian clinical prac-
tice, and UK-specific unit costs, we estimated the total
economic impact of FN including care for the initial event
as well as downstream FN-related care. The mean eco-
nomic burden of FN (i.e., the difference in costs between
FN patients and comparison patients) was found to be
substantial, totaling £5776 per patient. For FN patients
whose index event required hospitalization, economic bur-
den totaled £7259 (US$11,610), which is comparable to
the estimate (US$12,397) from the study by Weycker et al.
(2008) that employed the same study design and data from
a large US healthcare claims database (2001–2003) [9].
Most of the total economic burden was attributable to FN
inpatient admissions, since 76% of index events and 79%
of post-index events required hospitalization, and the
(unit) cost of such care is considerably higher than that
Table 3 Healthcare utilization among FN patients and matched comparison patients
Mean (95% CI)
Overall* Index Cycle Post-Index Cycle
Healthcare
Resources
FN Patients
(n = 295)
Comparison
Patients
(n = 295)
Difference FN Patients
(n = 295)
Comparison
Patients
(n = 295)
Difference FN Patients
(n = 295)
Comparison
Patients
(n = 295)
Difference
No. of FN Events 1.44(1.34, 1.56) 0.15(0.10, 0.21) 1.29(1.17, 1.43) 1.00(1.00, 1.00) 0.00(0.00, 0.00) 1.00(1.00, 1.00) 0.44(0.34, 0.56) 0.15(0.10, 0.21) 0.29(0.17, 0.43)
Requiring
Inpatient Care
1.10(1.00, 1.21) 0.13(0.08, 0.18) 0.98(0.85, 1.11) 0.76(0.71, 0.80) 0.00(0.00, 0.00) 0.75(0.70, 0.81) 0.35(0.26, 0.45) 0.13(0.08, 0.18) 0.22(0.12, 0.34)
Requiring
Outpatient Care
0.07(0.04, 0.11) 0.01(0.00, 0.03) 0.06(0.02, 0.09) 0.06(0.03, 0.09) 0.00(0.00, 0.00) 0.06(0.03, 0.09) 0.01(0.00, 0.03) 0.01(0.00, 0.03) 0.00(−0.02, 0.02)
Requiring
Home Care
0.18(0.12, 0.26) 0.01(0.00, 0.02) 0.17(0.10, 0.24) 0.12(0.08, 0.16) 0.00(0.00, 0.00) 0.12(0.08, 0.16) 0.06(0.02, 0.11) 0.01(0.00, 0.02) 0.05(0.01, 0.10)
Requiring Other
Care/No Action
0.05(0.02, 0.08) 0.00(0.00, 0.00) 0.05(0.02, 0.08) 0.04(0.02, 0.06) 0.00(0.00, 0.00) 0.04(0.02, 0.06) 0.01(0.00, 0.02) 0.00(0.00, 0.00) 0.01(0.00, 0.02)
Requiring
Unknown Care
0.04(0.02, 0.08) 0.00(0.00, 0.00) 0.04(0.02, 0.08) 0.03(0.01, 0.08) 0.00(0.00, 0.00) 0.03(0.01, 0.05) 0.01(0.00, 0.03) 0.00(0.00, 0.00) 0.01(0.00, 0.03)
Use of Healthcare Services
Inpatient Setting
Admissions 1.10(1.00, 1.21) 0.13(0.08, 0.18) 0.98(0.85, 1.11) 0.76(0.71, 0.80) 0.00(0.00, 0.00) 0.75(0.70, 0.81) 0.35(0.26, 0.45) 0.13(0.08, 0.18) 0.22(0.12, 0.34)
Days in Hospital 6.21(5.28, 7.17) 0.63(0.30, 1.02) 5.62(4.64, 6.62) 4.13(3.56, 4.78) 0.00(0.00, 0.00) 4.15(3.57, 4.81) 2.08(1.40, 2.75) 0.63(0.30, 1.02) 1.48(0.74, 2.23)
G-CSF (# admin.) 0.51(0.31, 0.75) 0.05(0.01, 0.10) 0.46(0.26, 0.69) 0.37(0.22, 0.53) 0.00(0.00, 0.00) 0.37(0.22, 0.53) 0.14(0.03, 0.27) 0.05(0.01, 0.10) 0.10(−0.03, 0.26)
Filgrastim 0.33(0.18, 0.51) 0.03(0.00, 0.08) 0.30(0.15, 0.49) 0.23(0.13, 0.34) 0.00(0.00, 0.00) 0.23(0.13, 0.33) 0.10(0.01, 0.23) 0.03(0.00, 0.08) 0.07(−0.03, 0.22)
Pegfilgrastim 0.00(0.00, 0.01) 0.00(0.00, 0.01) 0.00(−0.01, 0.01) 0.00(0.00, 0.01) 0.00(0.00, 0.00) 0.00(0.00, 0.01) 0.00(0.00, 0.00) 0.00(0.00, 0.01) 0.00(−0.01, 0.00)
Other Agent 0.18(0.06, 0.33) 0.01(0.00, 0.04) 0.16(0.04, 0.31) 0.14(0.04, 0.27) 0.00(0.00, 0.00) 0.14(0.04, 0.25) 0.04(0.00, 0.11) 0.01(0.00, 0.04) 0.03(−0.03, 0.10)
IV Antimicrobials
(# admin.)
4.46(2.68, 7.51) 0.42(0.20, 0.68) 3.98(2.26, 6.89) 2.04(1.64, 2.47) 0.00(0.00, 0.00) 2.05(1.64, 2.48) 2.42(0.83, 5.25) 0.42(0.20, 0.68) 1.94(0.37, 4.70)
Outpatient Setting
G-CSF (# admin.) 0.27(0.11, 0.47) 0.33(0.10, 0.62) −0.06 (−0.27, 0.13) 0.03(0.00, 0.06) 0.00(0.00, 0.00) 0.03(0.00, 0.06) 0.24(0.08, 0.43) 0.33(0.10, 0.62) −0.09(−0.30, 0.10)
Filgrastim 0.19(0.05, 0.37) 0.24(0.02, 0.50) −0.05 (−0.25, 0.12) 0.02(0.00, 0.05) 0.00(0.00, 0.00) 0.02(0.00, 0.04) 0.17(0.04, 0.36) 0.24(0.02, 0.50) −0.07(−0.27, 0.11)
Pegfilgrastim 0.08(0.03, 0.13) 0.09(0.03, 0.17) −0.01(−0.10, 0.08) 0.01(0.00, 0.03) 0.00(0.00, 0.00) 0.01(0.00, 0.03) 0.06(0.02, 0.12) 0.09(0.03, 0.17) −0.02(−0.11, 0.66)
Other Agent 0.00(0.00, 0.01) 0.00(0.00, 0.00) 0.00(0.00, 0.01) 0.00(0.00, 0.01) 0.00(0.00, 0.00) 0.00(0.00, 0.01) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00)
IV Antimicrobials
(# admin.)
0.00(0.00, 0.00) 0.02(0.00, 0.07) −0.02(−0.07, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.02(0.00, 0.07) −0.02(−0.07, 0.00)
Home Setting
G-CSF (# admin.) 6.29(5.09, 7.54) 5.13(4.08, 6.28) 1.17(−0.30, 2.66) 0.13(0.04, 0.22) 0.01(0.00, 0.04) 0.11(0.03, 0.21) 6.16(4.99, 7.41) 5.12(4.07, 6.26) 1.06(−0.39, 2.52)
Filgrastim 2.35(1.60, 3.24) 2.20(1.46, 3.01) 0.16(−0.89, 1.24) 0.07(0.02, 0.14) 0.00(0.00, 0.03) 0.06(0.00, 0.13) 2.28(1.53, 3.18) 2.19(1.46, 2.99) 0.10(−0.95, 1.17)
Pegfilgrastim 1.07(0.88, 1.29) 0.96(0.77, 1.17) 0.12(−0.18, 0.38) 0.01(0.00, 0.02) 0.00(0.00, 0.01) 0.00(−0.01, 0.02) 1.07(0.88, 1.28) 0.96(0.77, 1.17) 0.11(−0.18, 0.38)
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Table 3 Healthcare utilization among FN patients and matched comparison patients (Continued)
Other Agent 2.86(1.92, 3.97) 1.97(1.19, 2.83) 0.90(−0.21, 2.03) 0.05(0.00, 0.11) 0.00(0.00, 0.00) 0.05(0.00, 0.11) 2.81(1.89, 3.92) 1.97(1.19, 2.83) 0.85(−0.25, 1.98)
IV Antimicrobials
(# admin.)
1.05(0.68, 1.47) 0.03(0.00, 0.09) 1.01(0.62, 1.45) 0.60(0.37, 0.87) 0.00(0.00, 0.00) 0.60(0.37, 0.86) 0.45(0.17, 0.78) 0.03(0.00, 0.09) 0.41(0.14, 0.74)
Other/Unknown Setting
G-CSF (# admin.) 0.69(0.41, 1.02) 0.87(0.31, 1.57) −0.18(−0.96, 0.47) 0.00(0.00, 0.01) 0.00(0.00, 0.00) 0.00(0.00, 0.01) 0.69(0.40, 1.02) 0.87(0.31, 1.57) −0.19(−0.97, 0.47)
Filgrastim 0.45(0.18, 0.77) 0.66(0.15, 1.33) −0.23(0.94, 0.39) 0.00(0.00, 0.01) 0.00(0.00, 0.00) 0.00(0.00, 0.01) 0.45(0.18, 0.76) 0.66(0.15, 1.33) −0.23(0.94, 0.39)
Pegfilgrastim 0.23(0.14, 0.34) 0.15(0.07, 0.23) 0.09(−0.04, 0.22) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.23(0.14, 0.34) 0.15(0.07, 0.23) 0.09(−0.04, 0.22)
Other Agent 0.01(0.00, 0.04) 0.06(0.00, 0.17) −0.04(−0.16, 0.03) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.01(0.00, 0.04) 0.06(0.00, 0.17) −0.04(−0.16, 0.03)
IV Antimicrobials
(# admin.)
0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00)
*Mean levels of resource use from index cycle through end of the chemotherapy course.
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Table 4 Healthcare costs among FN patients and matched comparison patients
Healthcare
Resources
Mean (95% CI), in British pounds
Overall* Index Cycle Post-Index Cycles
FN Patients
(n = 295)
Comparison
Patients
(n = 295)
Difference FN Patients
(n = 295)
Comparison
Patients
(n = 295)
Difference FN Patients
(n = 295)
Comparison
Patients
(n = 295)
Difference
Total Cost
of FN, Overall
8,066
(7,277, 8,882)
2,290
(1,923, 2,655)
5,776
(4,928, 6,713)
4,051
(3,633, 4,485)
— 4,051
(3,633, 4,485)
4,015
(3,374, 4,724)
2,290
(1,923, 2,655)
1,725
(978, 2,498)
Inpatient Care 6,007
(5,278, 6,771)
543
(287, 858)
5,463
(4,709, 6,322)
3,942
(3,520, 4,372)
— 3,942
(3,520, 4,372)
2,065
(1,478, 2,694)
543
(287, 858)
1,522
(900, 2,180)
Outpatient Care 180
(123, 252)
130
(56, 219)
50
(−37, 144)
65
(43, 89)
— 65
(43, 89)
115
(62, 182)
130
(56, 219)
−15 (−97, 74)
Home Care 1,673
(1,452, 1,899)
1,447
(1,220, 1,674)
225
(−78, 545)
41
(26, 59)
— 41
(26, 59)
1,632
(1,409, 1,853)
1,447
(1,220, 1,674)
184
(−117, 503)
Other/Unknown Care 207
(135, 293)
169(97, 253) 38
(−67, 152)
4(2, 5) — 4(2, 5) 203
(131, 289)
169
(97, 253)
34
(−71, 148)
Total Cost of FN, by Setting of Care
Inpatient Episode 9,688
(8,709, 10,653)
2,430
(1,984, 2,931)
7,259
(6,327, 8,205)
5,281
(4,810, 5,774)
— 5,281
(4,810, 5,774)
4,407
(3,613, 5,225)
2,430
(1,984, 2,931)
1,978
(1,262, 2,801)
Outpatient Episode 3,761
(1,908, 6,007)
1,777
(1,116, 2,565)
1,984
(−193, 4,177)
341
(293, 435)
— 341
(293, 435)
3,420
(1,529, 5,676)
1,777
(1,116, 2,565)
1,644
(−521, 3,853)
Home Episode 3,291
(2,445, 4,339)
1,826
(993, 2,919)
1,466
(234, 2,495)
324
(241, 415)
— 324
(241, 415)
2,967
(2,124, 4,059)
1,826
(993, 2,919)
1,141
(−99, 2,176)
Other/Unknown Episode 2,211
(1,140, 3,425)
1,850
(766, 3,157)
361
(−956, 1,650)
104
(51, 205)
— 104
(51, 205)
2,107
(1,052, 3,333)
1,850
(766, 3,157)
258
(−1,031, 1,558)
*Mean costs from index cycle through end of the chemotherapy course.
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http://www.biomedcentral.com/1471-2407/12/362for FN treated in the outpatient or home care settings. As
in the study by Weycker and colleagues, while the burden
of the initial event was substantial and accounted for the
majority of FN-attributable costs (70%), a significant mi-
nority of these costs resulted from follow-on care and sub-
sequent events underscoring the economic importance of
accounting for the downstream consequences of this com-
plication. The economic costs of index events averaged
£4051, versus £1725 for FN-related healthcare utilization
in post-index cycles.
For several reasons, our estimates of the total eco-
nomic burden of FN may be conservative. First, for FN
events requiring hospitalization, follow-on care that may
have occurred in the outpatient setting subsequent to
hospital discharge--in the index cycle or subsequently--
was not collected during the IMPACT NHL study and
thus could not be incorporated into our estimates of dis-
ease burden. Second, for all FN events--irrespective of
care setting--additional resources that may have been
used (e.g., laboratory supplies), and additional services
that may have been provided (e.g., drug administration),
in the treatment of FN--and that are not included in
assumed unit costs/reimbursed values--could not be
incorporated due to data limitations. Finally, we erred
on the conservative side when making assumptions
about the frequency and intensity of resource use out-
side the hospital setting--where such data were not avail-
able from the IMPACT NHL Study--and thus may have
underestimated corresponding costs of care. We also
note that estimates of disease burden were robust when
employing the alternative (i.e., more stringent) matching
criteria for FN patients and comparison patients, when
admissions designated as “elective” were excluded from
estimation of (unit) cost of hospital care, and when using
Payment by Results (PbR) tariffs (rather than NHS refer-
ence costs) for hospital care (data available in Additional
file 1: Tables S6-S8 of the online supplement).
Several limitations of our study are noteworthy. First,
although FN patients and comparison patients were
matched on several characteristics, it is possible that the
two cohorts differed in terms of unobserved characteris-
tics that predispose them to FN. To the extent that FN
patients in our study population were more likely to de-
velop FN than comparison patients, some downstream
costs--in particular, those occurring in cycles after the
one in which the initial (i.e., index) FN event occurred--
may not be attributable to the initial FN event per se.
Especially problematic in this regard are the costs of
subsequent FN events. To what extent does experiencing
a first episode of FN increase a patient’s risk of subse-
quent episodes, relative to the extent to which the risk
of subsequent episodes is predicted by the same risk fac-
tors associated with the initial episode? If largely the lat-
ter, the actual burden of chemotherapy-induced FN maybe closer to the total costs of the index event plus any
additional follow-on care that is directly related to the
initial event--most of which, presumably, would occur in
the same cycle. Second, it is possible that certain biases
in recording may exist such that patients who experience
an FN event may be more likely to have FN noted on fu-
ture encounters versus patients without a history of
these complications, all else equal, which could upwardly
bias our estimates. Third, although FN-related health-
care utilization appears to be comparable across coun-
tries, differences between the UK and other countries in
the services or intensity of services that are provided
within a given setting (and that are not captured in the
study database) are not reflected in study results. Ac-
cordingly, caution should be exercised in generalizing
the results of this study to other settings. Fourth, we
note that FN patients comprise those whose index
course was their first course of chemotherapy as well as
those who previously received chemotherapy. To the ex-
tent that the consequences of FN are different based on
prior receipt of chemotherapy, results may not be
generalizable to these two subgroups (i.e., subgroups
comprising solely patients who previously received
chemotherapy and those who did not, respectively).
Fifth, we note that various patient- and provider-specific
factors may influence the pattern and intensity of FN
treatment, on an inpatient and outpatient basis, and that
to the extent these factors vary across settings, study
results may not be fully generalizable to other patient
populations. Sixth, the IMPACT NHL Study was not
designed for economic analyses, and thus data on certain
types of healthcare utilization (e.g., outpatient visits for
follow-on care) were not collected, while other data (e.g.,
identification and use of IV antimicrobial agents as treat-
ment or prophylaxis) may not always have been col-
lected or classified consistently and comprehensively.
Therefore, the results of this analysis may underestimate
the total attributable cost of FN. Finally, while our study
population comprised adult patients with NHL, we note
that the Healthcare Resource Group version 4 (HRG4)
code--PA45Z--that was used to cost FN-related inpatient
care is grouped in the chapter “Diseases of Childhood
and Neonates”. We also note, however, that this code
has been employed in several single technology apprai-
sals (STAs) and evidence review group’s (ERG) reports
to cost chemotherapy-related febrile neutropenia among
adults with HER2-negative metastatic breast cancer,
adults with chronic lymphocytic leukemia, adults with
metastatic prostate cancer, and adults with squamous cell
carcinoma of the head and neck, respectively [15-18].
Conclusion
In conclusion, the economic burden of FN among NHL
patients in European and Australian clinical practice is
Weycker et al. BMC Cancer 2012, 12:362 Page 12 of 13
http://www.biomedcentral.com/1471-2407/12/362substantial, and a significant proportion of this burden is
due to the downstream consequences of the condition.
Studies focusing only on the initial FN event may under-
estimate the total attributable cost of these complications.Additional file
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